ABSI - Absci Corp

ABSI - Absci Corp

https://www.absci.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Absci Boosts AI-Powered Drug Discovery With Oracle And AMD Collaboration - Absci ( NASDAQ:ABSI )

Benzinga • 4 days, 1 hour ago • score: 0.07

Absci uses OCI's AMD EPYC-powered bare metal instances to speed up molecular simulations and antibody design. Hypervisor overhead is cut, inter-GPU latency drops to 2.5 µs, and data throughput reaches terabytes per second. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

GlobeNewswire • 4 days, 5 hours ago • score: 0.34

Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs ...

Absci to Participate in Upcoming Investor Conferences

GlobeNewswire • 3 weeks, 5 days ago • score: 0.54

VANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Absci Corporation ( Nasdaq: ABSI ) , a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor ...

Absci Sales Fall 54 Percent

Motley Fool • 1 month ago • score: 0.20

Absci ( NASDAQ:ABSI ) , a biotechnology company focused on generative AI-driven drug discovery, issued its second quarter fiscal 2025 earnings on August 12, 2025. The release highlighted a steep revenue decline and wider losses, overshadowing operational progress in the pipeline and platform ...

Absci Corporation ( ABSI ) Reports Q2 Loss, Misses Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.11

ABSCI CORP (ABSI) delivered earnings and revenue surprises of -26.32% and -74.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

GlobeNewswire • 1 month, 1 week ago • score: 0.45

BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Almirall ( BME: ALM ) , a global biopharmaceutical company focused on medical dermatology, and Absci Corporation ( Nasdaq: ABSI ) , a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

None

52W High

$6.33

52W Low

$2.01

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.02

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.39

EV/Revenue (<3 favorable)

59.41

P/S (TTM) (<3 favorable)

86.00

P/B (<3 favorable)

2.05

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

9.25%

Institutions (25–75% balanced)

60.02%

Shares Outstanding

149,523,000

Float

132,154,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

4,138,000

Gross Profit (TTM)

-67,646,000

EPS (TTM)

-0.95

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-52.94%

ROE (TTM) (>15% strong)

-0.57%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.53

Momentum

Bearish momentum

Value

-0.0861

Previous

-0.0959

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025